Register for IPO Updates
US IPO Stats
IPO Industry Breakdown
Largest Global IPOs
Largest US IPOs
IPO News Archive
New Ways to Invest in IPOs - IPO ETFs
US IPO Weekly Recap: 2016 IPO market kicks off with a flurry of biotech filings
Analyst IPO Market Commentary
Biotech IPOs show their resilience, yet again.
Twelve IPOs filed this week, including nine biotechs -
more biotech IPO filings than any week last year
. The sub-sector that powered the 2015 IPO market (35% of the 170 deals) ended last year battered down to a +3% gain, compared to +41% for biotechs at the end of 2014. Of the last 20 IPO filings, health care accounts for 65% and technology is 25% - the depressed tech sector saw notable filers Nutanix (
) and SecureWorks (
) in December. However, filing for an IPO is one thing - getting the deal done will be another.
The VIX Volatility Index, which has a
close inverse relationship to IPO activity
closed above 25 for the first time since September
. With a crash in commodities and big trouble in China's markets, the S&P 500 ended the week down 6% - the worst opening week in its history. The average IPO from 2015 now trades -11% below its offer price. Even recent IPOs from the 4Q15, which faced intense valuation pressure, saw total average returns drop to +6% from +17% last week, while their post first-day trading swung negative. Expect more pricing pressure in the beginning of 2016.
Biotech investors go for seconds
14 biotechs priced secondary offerings
this past week. The biotechs fell -2% on average from the offer price, after pricing -18% below where they were trading at the announcement of the offering. Their return was unimpressive, but far better than that of the Nasdaq Biotech Index, which plummeted -11% this past week. While the pre-revenue biotech sector does not experience traditional multiple contraction, IPO investors may instead seek greater discounts, with an eye on venture investors' last private round.
Down but not out: Nine biotechs file for IPOs
The flurry of biotech filings contains several IPOs that should not get lost in the crowd.
) will test IPO investors' appetite for a hot biotech at an extremely early stage - human trials expected to begin in 2017. Leveraging CRISPR gene editing technology, Editas has raised over $200 million from a group of top-tier investors including Deerfield, Fidelity, Google, Polaris and Third Rock.
), also in preclinical studies, was the largest biotech IPO filer this past week with a $115 million deal size. Backed by OrbiMed, Adams Street and Fidelity, Corvus is developing checkpoint immunotherapies for tumors, another promising space. After postponing an IPO in 2014,
) is back with a new use for its drug candidate - checkpoint immunotherapy - along with a new $80 million funding round from top investors in August and the former CMO of AstraZeneca leading the company. After netting $65 million in a Series C in October (OrbiMed, Sofinnova, Redmile),
) plans to raise $86 million as it develops one-shot gene therapies for rare but fatal diseases. Backed by Polaris and Merck,
) has an ambitious plan to create a universal flu vaccine that both treats and prevents all strains of the disease; its $69 million IPO could take it the rest of the way through Phase 2 trials. Pulmonary arterial hypertension biotech
) is seeking $80 million as it plans a Phase 3 trial. T-cell biotech
) filed to raise $86 million.
Three non-biotechs: Argentina bank,
and avoiding adverse drug events with IT
Controlled by CEO Julio Supervielle, Argentina-based bank
) filed to raise $100 million in the US less than one month after the country's currency began free-floating, weakening about 30% compared to the dollar. Founder and CEO-owned
) plans to raise $100 million to pay down debt ($428mm; 8.5x LTM adj. EBITDA), which the company took on to rapidly expand its concession stores into new airport terminals (+42% yoy growth; $359mm LTM sales). Venture-backed
Tabula Rasa HealthCare
), which offers risk management IT solutions to health care providers, filed to raise $115 million. It grew sales by 45% to $50 million during the first nine months of 2015, at a 30% gross margin.
M&A update: Medical device IPO acquisitions
High-growth medical device maker
), on file for a $75 million IPO, announced that it would be acquired for $380 million. Another medical device maker,
), officially withdrew its IPO after announcing its acquisition in November. If markets remain turbulent, more IPO filers may explore their M&A options.
Failure to launch: No IPOs added to the calendar
Even as biotechs piled into the IPO pipeline, poor market conditions likely deterred companies from joining the
. Only Shimmick Construction (
) is scheduled for next week in a $75 million IPO.
12 filings during the week of January 4, 2016
Deal size ($mm)
Bavarian Nordic (
Biotech: Vaccines that stimulate T-cells
Audentes Therapeutics (
Biotech: Gene therapy for muscular diseases
Editas Medicine (
Biotech: Gene editing based on CRISPR
Tabula Rasa HealthCare (
IT solutions for health care management
Reata Pharmaceuticals (
Biotech: Protein-based anti-inflammation
Syndax Pharmaceuticals (
Biotech: Enhanced immuno-oncology
Corvus Pharmaceuticals (
Biotech: Immunotherapy for solid tumors
Spring Bank Pharmaceuticals (
Biotech: Viral disease platform
Biotech: Universal flu vaccine
Grupo Supervielle (
Argentina bank with $2B in assets
OTG EXP (
Operates 220 restaurants in 10 airports
Clearside Biomedical (
Biotech: Diseases that cause blindness
Find out why institutional investors rely on Renaissance Capital's
for these IPOs.
Follow us on Twitter (
) for IPO news as it happens and
register for our updates
on the IPO market.
IPO Market Snapshot
In 2015, 170 companies raised $30 billion. The Renaissance IPO Indices are market cap weighted baskets of newly public companies. The Renaissance IPO Index is down 7% year-to-date, compared to -6% for the S&P 500. Renaissance Capital's IPO ETF (NYSE: IPO) tracks the index, and
top ETF holdings
include Synchrony Financial (
), Alibaba (
) and Citizens Financial Group (
). The Renaissance International IPO Index is down 2% year-to-date, compared to -7% for ACWX. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and
top ETF Holdings
include Recruit Holdings and NN Group.
Keywords / Tickers:
Recently Priced IPOs
ETF Express Award:
ETFExpress awards are based on a 'peer review system' whereby readers - including institutional and high net worth investors as well as managers and other industry professionals at fund administrators, brokers, custodians and advisers - are invited to elect a 'best in class' in a series of categories via an online survey. In each category, the firms with the most votes at the end of the voting period are subject to a final review by ETFExpress's Senior Editorial team.
Past performance does not guarantee future results. The performance data quoted represents past performance and current returns may be lower or higher. The investment return and principal value of an investment will fluctuate so that an investor's shares, when redeemed, may be worth more or less than the original cost. Investors should consider the investment objectives, risks, charges and expenses carefully before investing.
As stated in the Prospectus, the total annual operating expenses for the Fund was 3.48%. The Adviser has contractually agreed to keep net expenses from exceeding 2.50% of the Fund's average daily net assets for at least a year from the date of the Prospectus and for an indefinite period thereafter subject to annual re-approval of the agreement by the Board of Trustees.
An investor cannot invest directly in an index. Index returns do not represent Fund returns. The Index does not charge management fees or brokerage expenses, nor does the Index lend securities, and no revenues from securities lending were added to the performance shown.
Definitions: Net Asset Value (NAV) of the fund is calculated by dividing the total value of all the securities in its portfolio, less any liabilities, by the number of fund shares outstanding. Market Price is current value at which an asset or service can be bought or sold. Premium/Discount is provided to show the comparison of the daily net asset value (NAV) and the midpoint of the closing bid/ask for each of the funds. The
Renaissance IPO Index® (IPOUSA)
is a stock market index based upon a portfolio of U.S.-listed newly public companies that includes securities prior to their inclusion in core U.S. equity portfolios. The
Renaissance International IPO Index® (IPOXUS)
is a stock market index based upon a portfolio of newly public companies listed on non-U.S. exchanges. The S&P 500® Index (SPX) is a stock market index which includes 500 U.S. listed companies and seeks to capture approximately 80% coverage of available U.S. market capitalization.
Risk Disclosure: Investments in the
Renaissance IPO ETF, symbol "IPO"
Renaissance International IPO ETF, symbol "IPOS"
(the "ETFs"), and the
Global IPO Fund, symbol "IPOSX"
(the "Mutual Fund") are subject to investment risk, including possible loss of the principal amounts invested. The ETFs and the Mutual Fund (the "Funds") invest in companies that have recently completed initial public offerings. These stocks are unseasoned equities lacking trading history, a track record of reporting to investors and widely available research coverage which many result in extreme price volatility. Due to a greater number of IPOs in certain segments, the Funds may also be subject to information technology and financial sector risk, small and mid-capitalization company risk, and, for the Renaissance International IPO ETF, emerging markets risk. The Funds may hold securities in the form of Depository Receipts, REITs, and Partnership Units which have greater risks than common shares. The strategies have high portfolio turnover and securities lending risks. The returns of the ETFs may not match the return of the respective indices. The ETFs are classified as non-diversified investment companies subject to concentration risk.
Prospectus: Investors should consider the investment objectives, risks, charges and expenses carefully before investing. For a prospectus and/or summary prospectus with this and other information, please visit
. Read the prospectus carefully before investing. Renaissance Capital Investments, Inc., distributor for the Mutual Fund. Foreside Fund Services, LLC, distributor for the ETFs, 1-866-486-6645.
Definitions: The Renaissance IPO Index® is a stock market index based upon a portfolio of U.S.-listed newly public companies that includes securities prior to their inclusion in core U.S. equity portfolios. The S&P 500® Index is a stock market index based on the market capitalizations of 500 large companies whose common stock is publicly traded on the NYSE.
The information contained herein is proprietary and copyrighted. The media is welcome to use our information and ideas, provided that the following sourcing is included: Renaissance Capital - manager of IPO-focused ETFs.
The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO), the Renaissance International IPO ETF (symbol: IPOS), or the Global IPO Fund (symbol: IPOSX), may have investments in securities of companies mentioned.
Register for Updates
Renaissance Capital LLC is an SEC-registered investment adviser.
Renaissance Capital Investments, Inc. is a
-registered broker-dealer, and member of
© 2016 Renaissance Capital LLC. All rights reserved.